title: HCV direct-acting antiviral agents: the best interferon-free combinations.
abstract: For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan-genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross-resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.
authors.affiliation: Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: Raymond
authors.initials: R
authors.lastname: Schinazi
authors.forename: Philippe
authors.initials: P
authors.lastname: Halfon
authors.forename: Patrick
authors.initials: P
authors.lastname: Marcellin
authors.forename: Tarik
authors.initials: T
authors.lastname: Asselah
mesh_terms: D000621:Aminoisobutyric Acids; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates; D002986:Clinical Trials as Topic; D060740:Disease Eradication / Q000379:methods / Q000639:trends*; D055808:Drug Discovery / Q000379:methods*; D004359:Drug Therapy, Combination / Q000379:methods* / Q000639:trends; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring; D006801:Humans; D007093:Imidazoles; D016898:Interferon-alpha; D007546:Isoquinolines; D007930:Leucine / Q000031:analogs & derivatives; D009842:Oligopeptides; D011092:Polyethylene Glycols; D011392:Proline / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000494:pharmacology; D011759:Pyrrolidines; D011804:Quinolines; D011994:Recombinant Proteins; D012254:Ribavirin; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides; D013844:Thiazoles; D014542:Uridine Monophosphate / Q000031:analogs & derivatives; D014633:Valine / Q000031:analogs & derivatives; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000187:drug effects / Q000502:physiology*; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000621:Aminoisobutyric Acids; D000998:Antiviral Agents; D002219:Carbamates; D006575:Heterocyclic Compounds, 3-Ring; D007093:Imidazoles; D016898:Interferon-alpha; D007546:Isoquinolines; D007930:Leucine; D009842:Oligopeptides; D011092:Polyethylene Glycols; D011392:Proline; D011480:Protease Inhibitors; D011759:Pyrrolidines; D011804:Quinolines; D011994:Recombinant Proteins; D012254:Ribavirin; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides; D013844:Thiazoles; D014542:Uridine Monophosphate; D014633:Valine; D017361:Viral Nonstructural Proteins; C552340:faldaprevir; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; C549273:daclatasvir; C100416:peginterferon alfa-2a; C571889:asunaprevir
keywords: asunaprevir; daclatasvir; faldaprevir; pegylated interferon; ribavirin; simeprevir; sofosbuvir